Ross A. Soo

National University Cancer Institute, Singapore — Singapore

Medicine · Health Sciences

69h-index19.3kcitations683works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(438), Colorectal Cancer Treatments and Studies(124), Lung Cancer Research Studies(115), Lung Cancer Diagnosis and Treatment(113), Cancer Genomics and Diagnostics(80)

Publications680 total

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials
Journal of Thoracic Oncology·2026
A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancer
Therapeutic Advances in Medical Oncology·2025Open Access
Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary PLS from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Table S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Table S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Table S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
2025Open Access
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population
npj Precision Oncology·2025Open Access
A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America
Frontiers in Oncology·2025Open Access
P2.06.14 Adoption of a 50-Gene Targeted Next Generation Sequencing Hotspot Panel in Non-Small Cell Lung Cancer in a Tertiary Institution in Singapore
Journal of Thoracic Oncology·2025
P1.17.24 Mixed Methods IASLC Global Survey and Provider Interview Study of Us NSCLC Biomarker Testing Practices and Clinical Processes
Journal of Thoracic Oncology·2025
PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC
Journal of Thoracic Oncology·2025· 2 cited
PT2.12.03 Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1
Journal of Thoracic Oncology·2025
P3.12.21 Biomarker Analysis and Final Efficacy of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2025
3163eP Immune checkpoint inhibitor–mediated hepatitis: Real-world experience from a tertiary unit in Asia
Annals of Oncology·2025
1505P A phase I study of MTL-CEBPA, atezolizumab (atezo) and bevacizumab (bev) in advanced hepatocellular carcinoma (HCC)
Annals of Oncology·2025
205eP Stool microbial signatures linked to immune checkpoint inhibitor response: A pan-tumour analysis in an Asian cohort
Annals of Oncology·2025
page 1 of 34Next →

Frequent Co-authors

Byoung Chul Cho(15), James Chih‐Hsin Yang(7), Solange Peters(7), Enriqueta Felip(6), Tony Mok(6), Wan‐Teck Lim(6), Dong‐Wan Kim(6), Yi‐Long Wu(6), Shun Lü(6), Richie Soong(6), Benjamin Solomon(5), Todd M. Bauer(5), Sai‐Hong Ignatius Ou(5), Alice T. Shaw(5), Daniel Shao-Weng Tan(5), Tan Min Chin(5), Gregory J. Riely(4), Eng Huat Tan(4), Ji‐Youn Han(4), Daniel S.W. Tan(4)